Advertisement
Screener

Savara Inc (SVRA) Borrowing debt

Savara Inc (SVRA) Borrowing debt

  • Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
  • Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
  • Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..

Borrowing debt

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Total debt · latest quarter (USD)(m)Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30.

Calculation unavailable: missing inputs remain (m).

Net cash · latest quarter(m)Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30.

Calculation unavailable: missing inputs remain (m).

Debt / assets · latest quarter(m)Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Borrowing debt due within one year0.00 USDLong-term Debt, Current Maturities
Borrowing debt due after one year30.11M USDLong-term Debt, Excluding Current Maturities
Commercial paper(m)
Cash and current securities(m)Cash and Cash Equivalents, at Carrying Value
Borrowing debt(m)Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities
Total assets192.14M USDAssets

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingTotal debtNet cash / debtBorrowing debt due within one year (USD)Borrowing debt due after one year (USD)Commercial paper (USD)Cash and current securities (USD)Total assets (USD)Debt / assets
2026-06-30(m)(m)$0.00$30.11M(m)(m)$192.14M(m)
2026-03-31(m)(m)$0.00$30.07M(m)(m)$221.65M(m)
2025-12-31(m)(m)$0.00$29.91M(m)(m)$253.44M(m)
2025-09-30(m)(m)$0.00$29.78M(m)(m)$140.92M(m)
2025-06-30(m)(m)$0.00$29.65M(m)(m)$163.76M(m)
2025-03-31(m)(m)$0.00$29.52M(m)(m)$189.32M(m)
2024-12-31(m)(m)(m)$26.62M(m)(m)$212.88M(m)
2024-09-30(m)(m)(m)$26.55M(m)(m)$238.82M(m)
2024-06-30(m)(m)(m)$26.48M(m)(m)$139.67M(m)
2024-03-31(m)(m)(m)$26.42M(m)(m)$158.29M(m)
2023-12-31(m)(m)(m)$26.35M(m)(m)$177.56M(m)
2023-09-30(m)(m)(m)$26.28M(m)(m)$182.07M(m)
2023-06-30(m)(m)(m)$26.21M(m)(m)$119.83M(m)
2023-03-31(m)(m)(m)$26.14M(m)(m)$129.36M(m)
2022-12-31(m)(m)(m)$26.08M(m)(m)$139.78M(m)
2022-09-30(m)(m)(m)$26.01M(m)(m)$147.76M(m)
2022-06-30(m)(m)(m)$25.94M(m)(m)$156.78M(m)
2022-03-31(m)(m)$12.50M$13.31M(m)(m)$166.21M(m)
2021-12-31(m)(m)$8.33M$17.32M(m)(m)$176.60M(m)
2021-09-30(m)(m)$4.17M$21.35M(m)(m)$187.27M(m)
2021-06-30(m)(m)(m)$25.38M(m)(m)$196.43M(m)
2021-03-31(m)(m)(m)$25.24M(m)(m)$207.63M(m)
2020-12-31(m)(m)(m)$25.10M(m)(m)$97.75M(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Seaport Therapeutics, Inc. (SPTX)United States$1.131B